Dr. Fyffe-Maricich received her PhD in Human and Molecular Genetics from Baylor College of Medicine. She completed her graduate training in the lab of Dr. Huda Zoghbi where she studied the contribution of specific neuronal subpopulations to the underlying biology of Rett Syndrome. Following her postdoctoral training at Case Western Reserve University in the field of central nervous system myelin biology, she joined the faculty at the University of Pittsburgh School of Medicine as an Assistant Professor of
Pediatric Neurology. Her laboratory focused on using genetic mouse models to understand the biology of MAP kinase signaling during oligodendrocyte development and in the repair of demyelinating lesions with the ultimate goal of finding novel treatments for patients with Multiple Sclerosis. Sharyl’s work was supported by the National Multiple Sclerosis Society and NIH R01 funding from the National Institute of
Neurological Disorders and Stroke (NINDS).

In 2016, Sharyl joined Ultragenyx Pharmaceutical, a commercial-stage biopharmaceutical company focused on developing novel and transformative treatments for patients with rare diseases, to lead their Molecular Biology Research team. As a trained neuroscientist, she also oversees the company’s preclinical research for all CNS programs and she is the team lead for a gene therapy program for the treatment of CDKL5 Deficiency Disorder.